Raymond James & Associates Black Diamond Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
BUY
$2.67 - $5.74 $63,105 - $135,664
23,635 New
23,635 $119,000
Q1 2021

May 14, 2021
SELL
$22.23 - $34.75 $165,991 - $259,478
-7,467 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$29.47 - $35.0 $766 - $910
-26 Reduced 0.35%
7,467 $239,000
Q3 2020

Nov 04, 2020
BUY
$26.17 - $43.07 $8,714 - $14,342
333 Added 4.65%
7,493 $227,000
Q2 2020

Jul 28, 2020
BUY
$22.3 - $44.8 $159,668 - $320,768
7,160 New
7,160 $302,000

Others Institutions Holding BDTX

# of Institutions
117
Shares Held
48.8M
Call Options Held
1.84M
Put Options Held
1.93M
View Full List

About Black Diamond Therapeutics, Inc.

BDTX Quotes by TradingView
  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $79.2M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email